previously medical experiments of CagriSema uncovered that it assisted people realize considerably greater weight loss than semaglutide (Wegovy) did. even when Lilly's Zepbound/Mounjaro topples Wegovy, it's feasible that CagriSema could enter the marketplace at the ideal time for Novo Nordisk to retain its overall Management during the obesity drug